Vir Biotechnology (VIR) Receivables (2020 - 2022)

Vir Biotechnology has disclosed Receivables across 3 years of filings, most recently posting $7.0 million for Q2 2022.

• Receivables for Q2 2022 came in at $7.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2022 was $7.0 million (changed N/A YoY), and the FY2021 annual result was $773.1 million, changed N/A from the prior year.
• Receivables came in at $7.0 million for Q2 2022 at Vir Biotechnology, down from $1.2 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $1.2 billion in Q1 2022 to a low of $3.8 million in Q2 2020.
• The 3-year median for Receivables is $159.0 million (2021), against an average of $387.5 million.
• Peak annual rise in Receivables reached 443.63% in 2022, while the deepest fall reached 443.63% in 2022.
• Vir Biotechnology's Receivables stood at $3.8 million in 2020, then surged by 20244.18% to $773.1 million in 2021, then plunged by 99.09% to $7.0 million in 2022.
• The last three Receivables figures came in at $7.0 million (Q2 2022), $1.2 billion (Q1 2022), and $773.1 million (Q4 2021), per Business Quant data.